1. Home
  2. FLGT vs NMRA Comparison

FLGT vs NMRA Comparison

Compare FLGT & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fulgent Genetics Inc.

FLGT

Fulgent Genetics Inc.

HOLD

Current Price

$15.77

Market Cap

525.3M

Sector

Health Care

ML Signal

HOLD

NMRA

Neumora Therapeutics Inc.

HOLD

Current Price

$1.88

Market Cap

554.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLGT
NMRA
Founded
2011
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
525.3M
554.0M
IPO Year
2016
2023

Fundamental Metrics

Financial Performance
Metric
FLGT
NMRA
Price
$15.77
$1.88
Analyst Decision
Buy
Buy
Analyst Count
3
8
Target Price
$28.33
$7.50
AVG Volume (30 Days)
516.5K
1.5M
Earning Date
05-01-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.23
EPS
N/A
N/A
Revenue
$18,730,000.00
N/A
Revenue This Year
$10.09
N/A
Revenue Next Year
$12.18
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.46
$0.66
52 Week High
$31.04
$3.65

Technical Indicators

Market Signals
Indicator
FLGT
NMRA
Relative Strength Index (RSI) 50.60 37.01
Support Level $15.39 $1.81
Resistance Level $16.70 $1.90
Average True Range (ATR) 0.69 0.21
MACD 0.12 -0.03
Stochastic Oscillator 70.33 12.61

Price Performance

Historical Comparison
FLGT
NMRA

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: